MT-228 (BPN-0026709) is a selective and blood-brain barrier permeable non-muscle myosin II inhibitor. MT-228 markedly improves tolerability by selectively targeting NMIIB ( K I = 1.5 μM) over CMII ( K I = 17 μM), and the sequence of SmMll MD is 83.6% identical to that of NMllB. MT-228 shows long-lasting efficacy in animal models of stimulant use disorder.
Products | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Signaling Pathways > Cytoskeleton | Products > Research Areas > Neurological Disease | Products > Signaling Pathways > Myosin
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.